 So I had an opportunity to grab the mic, so I thought I'd take advantage of it. Sorry, we just had actually Tuesday and Wednesday of this week, the first meeting of the Clinical Sequencing Exploratory Research Consortium. I'll tell you a little bit more about it real quick, but we just met Tuesday and Wednesday at a very exciting meeting. We met with the Return of Results Consortium, which consists of the LC programs and the clinical sequencing program, plus a number of R01s and R21 grants from our LC group, and obviously we talk about a lot of the same issues that are being discussed here. I'm going to steal one of Eric's slides and just comment. I've got the mic. The week before, a week ago today, I was at the TCGA Steering Committee, the Cancer Genome Atlas Steering Committee meeting, which is another one of my jobs, and I just have to comment. We have, this is of course the large comprehensive analysis of cancer genomes, and that group has three papers in press or under review right now, and we'll put out another five tumor projects probably by the end of this year. So in the understanding of the biology of genome, mostly understanding of the biology of disease area, we're still doing lots of work and building the foundations from which the data can be translated to the clinic, we hope. But now on the clinical sequencing program is really advancing the science of medicine. And as Dan and Terry mentioned, we've reissued the RFA. We had a very strong response to this RFA that was out a year and a half ago. And these are, this is a call for multidisciplinary teams that are really looking at the issues around bringing sequencing into the clinical workflow. So each application requires three components. One, a generation application of first a clinical project to drive everything that follows. We require a clinician to be a PI in the program. Project two is the translation of sequencing and interpretation and reporting to the physician and patient of the sequencing data and the variants they're associated. And then a very important LC component, project three, examining the ethical and psychosocial implications of bringing broad genomic data into the clinic. Variant discovery is actually secondary. We say that to point out. The real aim of this program is to understand some of the mechanisms involved in bringing broad genomics into the clinic. So this RFA has just been reissued a few weeks ago, HG-12009 with due date, application due date of July 26th. And just to say we have funded, we've made six awards from the first RFA. Half are involving cancer genomics and half in more complex disease or a very variety of diseases. And the ones that were successful in this RFA were those that really built very strong projects in all three areas. The ones that didn't take some of the psychosocial implications, the LC issues, seriously didn't do as well. This really requires that multi-disciplinary effort. There's also a coordination center. I won't go into too much, similar to what Terry described for the Genomic Medicine Projects. These are her slides. And then just real quick, I know a number of you have U01 awards from either NHGRI or other NIH institutes. Many NIH institutes are participating in this. This is an announcement that just came out recently from the Office of the Director. They have funds in bioethics at NIH and they're seeking basically competitive supplements to ongoing U01s that are involved in research related to protection of human subjects. And they're looking for particular ideas, projects in two areas. One, the effectiveness of current human subjects protections and the development of tools and methods to examine evolving evidence-based approaches to improve human subjects protections. And also the feasibility cost benefits and impacts of requiring consent for research on de-identified human specimens and data using novel models of consent. This is a very fast timeline. These, the ones that come to NHGRI will go to a special meeting of our council this summer for awards before the end of this fiscal year. So awards in September, the application receipt date is May 25th. So pretty quick. In this you have to have a current U01 to apply for these supplements. Okay. Any questions? I'll sit down.